Literature DB >> 22374294

Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer.

Tetsuro Baba1, Hidetaka Uramoto, Taiji Kuwata, Yasuhiro Chikaishi, Makoto Nakagawa, Tomoko So, Takeshi Hanagiri, Fumihiro Tanaka.   

Abstract

We assessed the prognostic value of the 'Zone-classification' which has been proposed by the Japanese Association for Lung Cancer (JALC) for mediastinal nodal metastases in non-small cell lung cancer (NSCLC). Among 357 NSCLC patients who underwent curative surgery, 46 patients with pathological (p) N2 disease were divided into two groups as follows: 32 patients in whom the nearer zone was involved were classified as the pN2a-1 group, and 14 patients in whom the further mediastinal node station was involved were classified as the pN2a-2 group. The proportions of patients with non-adenocarcinoma histology, with multiple station metastases with the involvement of four or more nodes, and who underwent pneumonectomy, were higher in the pN2a-2 group. The 'Zone-classification' proved to be a significant prognostic factor in a univariate analysis (the 5-year overall survival rate, 7.1% for pN2a-2 versus 21.9% for pN2a-1; P < 0.01). A multivariate analysis confirmed that pN2a-2 sub-classification (hazard ratio 2.77; P = 0.03) and undergoing pneumonectomy (hazard ratio 4.86; P < 0.01) were independent and significant factors in predicting a poor prognosis. In pN2 NSCLC patients, the involved mediastinal zone according to the primary tumour site was important in prediction of survival.

Entities:  

Mesh:

Year:  2012        PMID: 22374294      PMCID: PMC3352724          DOI: 10.1093/icvts/ivs058

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  14 in total

1.  Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Authors:  Y Ichinose; H Kato; T Koike; R Tsuchiya; T Fujisawa; N Shimizu; Y Watanabe; T Mitsudomi; M Yoshimura
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

2.  Prognostic value of single nodal zone metastasis in non-small-cell lung cancer.

Authors:  Moon Soo Kim; Hyun-Sung Lee; Jong Mog Lee; Jae Ill Zo; Geon Kook Lee; Byung-Ho Nam
Journal:  Eur J Cardiothorac Surg       Date:  2010-10       Impact factor: 4.191

3.  Significance of the number of positive lymph nodes in resected non-small cell lung cancer.

Authors:  Takayuki Fukui; Shoichi Mori; Kohei Yokoi; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2006-02       Impact factor: 15.609

4.  Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature.

Authors:  J F Vansteenkiste; P R De Leyn; G J Deneffe; T E Lerut; M G Demedts
Journal:  Lung Cancer       Date:  1998-01       Impact factor: 5.705

5.  Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: by terms of nodal stations, zones, chains, and a composite.

Authors:  Hui Zheng; Lin-mao Wang; Fang Bao; Ge-ning Jiang; Hui-kang Xie; Jia-an Ding; Xue-fei Hu; Chang Chen
Journal:  Lung Cancer       Date:  2011-05-06       Impact factor: 5.705

6.  Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography.

Authors:  Michael B Wallace; James Ravenel; Mark I Block; Mostafa Fraig; Gerard Silvestri; Stephan Wildi; Nathan Schmulewitz; Shyam Varadarajulu; Stacey Roberts; Brenda J Hoffman; Robert H Hawes; Carolyn E Reed
Journal:  Ann Thorac Surg       Date:  2004-05       Impact factor: 4.330

7.  Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

Authors:  Steven M Keller; Mark G Vangel; Henry Wagner; Joan H Schiller; Arnold Herskovic; Ritsuko Komaki; Randolph S Marks; Michael C Perry; Robert B Livingston; David H Johnson
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

Review 8.  Adjuvant treatment of resected lung cancer.

Authors:  Laveena Chhatwani; Elwyn Cabebe; Heather A Wakelee
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

Review 9.  Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.

Authors:  Andrea Billé; Ettore Pelosi; Andrea Skanjeti; Vincenzo Arena; Luca Errico; Piero Borasio; Maurizio Mancini; Francesco Ardissone
Journal:  Eur J Cardiothorac Surg       Date:  2009-05-22       Impact factor: 4.191

10.  Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients.

Authors:  Jing Li; Chun-Hua Dai; Shun-Bing Shi; Ping Chen; Li-Chao Yu; Jian-Rong Wu
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more
  2 in total

Review 1.  Controversies regarding T status and N status for non-small cell lung cancer.

Authors:  Yanli Mo; Jiayin Peng; Wenmei Su; Xinggui Chen; Aibing Wu; Jinmei Li; Zhixiong Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author's reply.

Authors:  Song-Tao Xu; Jia-Cheng Yin; Jun-Jie Xi; Qun Wang; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2020-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.